Alembic Pharma gets USFDA nod for generic cancer, arthritis injection

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its generic methotrexate injection, used to treat multiple cancers and arthritis conditions. The approval covers key dosage formats and confirms therapeutic equivalence to the reference drug by Hospira, enabling Alembic to market the injectable in the US. Methotrexate is widely used for treating cancers such as leukemia, osteosarcoma and breast cancer, as well as conditions like rheumatoid arthritis and severe psoriasis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gCi15TF
via IFTTT

Read More

Eye on aspirational India, medical tourism, Max Healthcare steps up bed capacity expansion

Max Healthcare Institute Ltd is expanding capacity to 10,000 beds over the next 3–4 years, investing ₹4,000–5,000 crore to meet rising domestic demand and boost medical tourism.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tGoLmXP
via IFTTT

Read More

Dr Reddy's gets nod to roll out generic oral semaglutide drug

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to Novo Nordisk's oral semaglutide (Rybelsus brand). Based on this clinical evidence, our product has received regulatory approval in India under the biosimilar regulatory pathway," a company spokesperson said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ni8MIN3
via IFTTT

Read More

Iran war impact: Essential drugs may cost up to 5% more, for now

The immediate net consumer impact could be 3-5% higher prices, or roughly similar to what consumers paid before the late-September cuts in GST rates. The industry expects the price increase to be in place for 3-4 months, with a rollback option once input costs stabilise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eh2Jf8A
via IFTTT

Read More

KKR-backed Baby Memorial to acquire 60% stake in Star Hospitals for ₹1,800 crore

Baby Memorial Hospital will acquire around 60% stake in the Hyderabad hospital chain's parent company, Unimed Healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c2ByIzk
via IFTTT

Read More

PM's AYUSH Premium Mark push sparks rise in global demand for 'Made in India' homeopathy: Experts

India's homeopathy sector is experiencing a significant surge in demand, both domestically and internationally. This growth is attributed to the government's AYUSH Premium Mark and NABL accreditation initiatives, which have enhanced quality assurance and global credibility for "Made in India" medicines. These certifications are fostering trust and enabling Indian companies to compete effectively in regulated markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CJG1U4F
via IFTTT

Read More

Bajaj Group enters healthcare: Rs 2,500 crore investment for integrated network

The Bajaj Group is entering the healthcare sector with an initial investment of Rs 2,000-2,500 crore to build Bajaj Integrated Health Systems (BIHS). This new entity will focus on an integrated continuum of care, including hospitals, day clinics, and home services, aiming for a pan-India footprint within 10-15 years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fvcnxb7
via IFTTT

Read More